In this issue...

·  From the Executive Director
Karen J. Hanson, Ph.D.

·  Upcoming Programs

·  Member News

Thank You to Our Sponsors

BioStrategy Partners is a virtual incubator providing technology and business development services to emerging stage life sciences companies in the Greater Philadelphia region. We specialize in offering business guidance and support to projects and nascent companies led by first-time entrepreneurs and scientific founders, helping them make it to the next level of commercialization. We offer a full range of support services designed especially for concept-stage and pre-seed companies, supplied through our network of expert volunteers, partners and service providers on a reduced fee, deferred compensation, or co-funded basis. We do not take equity and rely upon grants, sponsorships, fees, and earned income to support our operations.

From the Executive Director
Karen J. Hanson, Ph.D.

Temple University , representing a consortium composed of the academic-research partners in BioSP's KIZ, has been awarded a $189,523 Keystone Innovation Grant from the PA Department of Community & Economic Development. The grant, entitled Commercial Use of Human Antibodies in Cancer Therapy and awarded at the Collaboration 2008 conference earlier this month, is a true collaboration between Temple , the Lankenau Institute for Medical Research, Fox Chase Cancer Center , and Salus University (formerly the Pennsylvania College of Optometry). Congratulations to all!

The bench2BUSINESS Conference and Awards Celebration will be held on November 8-9, 2008. Designed as an unprecedented regional gathering of scientists, researchers, investors, and policymakers coming together to advance people of color in the business of the life sciences, the conference will feature two keynote speakers, hands-on, practical advice, and plenty of networking time. For more information, please call Phoenicia Williams at 215-384-1944 or email info@bench2business.org.

Upcoming Programs

Networking to the Next Degree: Learn how to create, communicate and modify your value proposition at events, trade shows and meetings
September 26, 2008
8:30AM - 11AM
Citizens Bank Gateway Center
3025 Chemical Road
Plymouth Meeting , PA 19462

Basic Intellectual Property Strategy for Early Stage Biotechnology Companies
October 30, 2008
8:30AM - 11AM
Lankenau Institute for Medical Research
100 Lancaster Avenue
Wynnewood , PA 19096

BioStrategy Partners Holiday Celebration
December, 2008

Member News

Dan Matlis, President of Axendia, reports that on September 18, Axendia made a presentation at the 2008 Master Summer in Snowbird, Utah on the findings and analysis of a recently completed study that identified key shifts in the FDA's organizational and technology infrastructures designed to facilitate electronic interaction with regulated companies. Dan chaired an executive workshop on "Entering the North American Market" at the Advamed 2008 MedTech Conference on September 21.

Linda Tedeschi, Marketing Associate at Richman Chemical, tells us that Frost & Sullivan interviewed Chris Kulp, Director of Contract Services Business at Richman Chemical for a report on the state of the fine chemicals market. The report discusses the stability of the fine chemicals market and analyzes indicators for growth through 2012. To read their findings, visit www.richmanchemical.com and click on the "News, Events and Links" page.

Fox Rothschild announced that it has combined with the 111-year old intellectual property law firm of Synnestvedt & Lechner (S&L) LLP, increasing the number of IP attorneys to 43, including 32 patent lawyers. Gerry Norton, Chair of Fox's IP Department said that, "Synnestvedt's strength is in the chemical and electrical areas of patent work and is an excellent complement to our strength in biotechnology, pharma and medical devices." According to Jeff Nicholas, Chair of the firm's Tech & Venture Finance practice, "Combining the financing acumen of Fox Rothschild's team of more than 30 tech and finance lawyers with our deep bench of IP experts enables us to help companies at every stage of development. It continues a pattern of smart, focused growth for the firm and reflects our commitment to helping early- and middle-stage life sciences companies seize new opportunities and protect and grow their assets."

Michael Brady of Brady Financial Group, LLC has been appointed to the Business & Operations Committee of the Great Rivers Affiliate of The American Heart Association with responsibility for PA,DE,WV,OH & KY.

Jennifer Kmiec, Vice President, Business Development and Marketing, of Newark, Delaware-based iBioPharma, Inc., (formerly InB:Biotechnologies), reports that the company is now independent, having spun off from its parent company Integrated BioPharma last month, and is trading on the OTC Bulletin Board under the ticker symbol "IBPM". At the same time, the company, which is developing vaccines and monoclonal antibodies produced in non-genetically-modified green plants, closed a $5 million private placement of common stock and warrants. More information is available at www.ibiopharma.com.